C12N 2310/13
Decoys
C12N2310/13 (Decoys) appears on 371 US grants and 449 published applications in this corpus.
Search patents in C12N- Granted patents
- 371
- Published applications
- 449
- Assignees
- 221
- Inventors
- 646
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 9 | 0 |
| 1997 | 25 | 0 |
| 1998 | 38 | 0 |
| 1999 | 17 | 0 |
| 2000 | 15 | 0 |
| 2001 | 19 | 3 |
| 2002 | 14 | 13 |
| 2003 | 6 | 30 |
| 2004 | 8 | 29 |
| 2005 | 6 | 21 |
| 2006 | 9 | 17 |
| 2007 | 3 | 17 |
| 2008 | 7 | 13 |
| 2009 | 14 | 25 |
| 2010 | 7 | 16 |
| 2011 | 13 | 13 |
| 2012 | 11 | 7 |
| 2013 | 4 | 8 |
| 2014 | 7 | 8 |
| 2015 | 8 | 11 |
| 2016 | 6 | 18 |
| 2017 | 9 | 15 |
| 2018 | 7 | 32 |
| 2019 | 30 | 40 |
| 2020 | 24 | 25 |
| 2021 | 16 | 32 |
| 2022 | 9 | 22 |
| 2023 | 9 | 10 |
| 2024 | 8 | 15 |
| 2025 | 3 | 6 |
| 2026 | 4 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions for herpesvirus transcriptional feedback circuit disruption and uses thereof21 Apr 2026US 12,606,829 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- microRNA inhibitors for use in treating metabolic diseases24 Mar 2026US 12,584,126 B2Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH)
- Nucleic acids and nucleic acid analogs for treating, preventing, and disrupting pathological polynucleotide-binding protein inclusions13 Jan 2026US 12,521,412 B2The Trustees of the University of Pennsylvania
- Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis13 Jan 2026US 12,523,663 B2Inserm (Institut National De La Santé Et De La Rescherche MéDicale)
- Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same21 Oct 2025US 12,448,624 B2Interoligo Corporation
- Decoy rna oligonucleotides for inhibiting ythdf224 Sep 2026US 2026/0286355 A1Catchme Rna Therapeutics Ltd.
- Antisense oligonucleotide, compositions and pharmaceutical formulations thereof for exon skipping30 Apr 2026US 2026/0117232 A1ASOcura Pharmaceuticals Suzhou Co., Ltd.
- Oligonucleotides for the treatment of breast cancer19 Mar 2026US 2026/0078376 A1Core Biotherapeutics, Inc.
- Modified u7 snrna construct20 Nov 2025US 2025/0354145 A1King's College London
- Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription8 May 2025US 2025/0146024 A1The Regents of the University of California
Most cited
By later US patents
- Methods for identifying nucleic acid ligands856US 5,270,163 AUniversity Research Corporation · 1993
- Nucleic acid ligands561US 5,475,096 AUniversity Research Corporation · 1995
- Systematic evolution of ligands by exponential enrichment: Solution SELEX337US 5,567,588 AUniversity Research Corporation · 1996
- Systematic evolution of ligands by exponential enrichment: chimeric selex281US 5,637,459 ANeXstar Pharmaceuticals, Inc. · 1997
- High-affinity nucleic acid ligands that discriminate between theophylline and caffeine277US 5,580,737 ANeXstar Pharmaceuticals, Inc. · 1996